Multivariate analysis for GDF-15 and survival in the 2 cohorts using cutoff values identified in initial testing cohort
| . | Athens . | Pavia . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Mayo stage | ||||||
| 1 | 1 | 1 | ||||
| 2 | 5.4 | 1.9-14.8 | .001 | 1.7 | 0.56-5.4 | .153 |
| 3A | 6.3 | 2-20 | <.001 | 2.1 | 0.8-7.5 | .108 |
| 3B | 9.6 | 3.1-29 | <.001 | 6.7 | 2.2-20.6 | <.001 |
| dFLC ≥180 mg/L | 1.15 | 0.67-1.9 | .734 | 2.5 | 1.4-4.6 | .01 |
| GDF−15 ≧7575 pg/mL | 2.0 | 1.1-3.6 | .023 | 1.92 | 1.1-3.35 | .022 |
| . | Athens . | Pavia . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Mayo stage | ||||||
| 1 | 1 | 1 | ||||
| 2 | 5.4 | 1.9-14.8 | .001 | 1.7 | 0.56-5.4 | .153 |
| 3A | 6.3 | 2-20 | <.001 | 2.1 | 0.8-7.5 | .108 |
| 3B | 9.6 | 3.1-29 | <.001 | 6.7 | 2.2-20.6 | <.001 |
| dFLC ≥180 mg/L | 1.15 | 0.67-1.9 | .734 | 2.5 | 1.4-4.6 | .01 |
| GDF−15 ≧7575 pg/mL | 2.0 | 1.1-3.6 | .023 | 1.92 | 1.1-3.35 | .022 |